Clozapine Rechallenge After Major Adverse Effects: Clinical Guidelines Based on 259 Cases

No abstract is available for this paper.

• Publication year

  2018

• Venue

  American Journal of Therapeutics

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MJT.0000000000000715PMID 29505490
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Developing Clinical Guidelines.

  2017cited by this paper
• Optimizing outcomes in clozapine rechallenge following neutropenia using human leukocyte antigen typing: A case report

  2017cited by this paper
• Development of Atrial Flutter After Initiation of Clozapine and Successful Rechallenge Without Recurrence.

  2017cited by this paper
• Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations

  2017cited by this paper
• Benign Ethnic Neutropenia and Clozapine Use: A Systematic Review of the Evidence and Treatment Recommendations.

  2016cited by this paper
• Clozapine Rechallenge After Neutropenia or Leucopenia

  2016cited by this paper
• Successful rechallenge with clozapine after treatment associated eosinophilia

  2016cited by this paper
• Systemic Inflammatory Response Syndrome Associated With Clozapine and Successful Rechallenge: A Case Report.

  2016cited by this paper
• Inflammatory response to clozapine in the absence of myocarditis: case report

  2016cited by this paper
• Case report of clozapine-induced neutropenia and rechallenge.

  2015cited by this paper
• Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis.

  2015cited by this paper
• INFORMED CONSENT AND E-COMMUNICATION IN MEDICINE

  2014cited by this paper
• The clinical case report: a review of its merits and limitations

  2014cited by this paper
• Informed Consent: How Much Awareness Is There?

  2014cited by this paper
• Successful Rechallenge of Clozapine Therapy Following Previous Clozapine-Induced Myocarditis Confirmed on Cardiac MRI

  2014cited by this paper
• Rechallenging Clozapine After Neuroleptic Malignant Syndrome

  2014cited by this paper
• Clozapine rechallenge following QTc prolongation

  2014cited by this paper
• Reintroduction of Clozapine After Perforation of the Large Intestine—A Case Report and Review of the Literature

  2013cited by this paper
• Rapid Re-challenge with Clozapine Following Pronounced Myocarditis in a Treatment-Resistance Schizophrenia Patient.

  2013cited by this paper
• Successful rechallenge with clozapine following ‘red alert’

  2013cited by this paper
• Add-on filgrastim during clozapine rechallenge unsuccessful in preventing agranulocytosis.

  2013cited by this paper
• Treatment-Resistant Schizophrenia: Prevalence and Risk Factors

  2013cited by this paper
• [Clozapine rechallenge in resistant schizophrenia disorder affecting "super sensitive" patients, after neutropenia under clozapine: a case report].

  2013cited by this paper
• Clozapine re-challenge under the cover of Filgrastim.

  2013cited by this paper
• Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far?

  2012cited by this paper
• Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation.

  2012cited by this paper
• Observations from 8 cases of clozapine rechallenge after development of myocarditis.

  2012cited by this paper
• When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature.

  2012cited by this paper
• Successful Clozapine Rechallenge after Acute Myocarditis

  2011cited by this paper
• Successful rechallenge with clozapine after eosinophilia.

  2011cited by this paper
• A New Monitoring Protocol for Clozapine-Induced Myocarditis Based on an Analysis of 75 Cases and 94 Controls

  2011cited by this paper
• Clozapine rechallenge after excluding the high-risk clozapine-induced agranulocytosis genotype of HLA-DQB1 6672G>C.

  2011cited by this paper
• Late-onset agranulocytosis in a patient treated with clozapine and lamotrigine.

  2011cited by this paper
• Monitoring in Clozapine Rechallenge After Myocarditis

  2011cited by this paper
• A case of agranulocytosis secondary to rechallenge with clozapine following severe neutropenia during previous therapy.

  2011cited by this paper
• Clozapine rechallenge following clozapine-induced pericarditis.

  2010cited by this paper
• Electroconvulsive Therapy in Treatment-Resistant Schizophrenia: Prediction of Response and the Nature of Symptomatic Improvement

  2010cited by this paper
• Clozapine rechallenge in refractory schizophrenia.

  2010cited by this paper
• Successful clozapine retrial after suspected myocarditis.

  2010cited by this paper
• Clozapine-induced bowel infarction: a case report.

  2009cited by this paper
• Prevalence, phenotype and inheritance of benign neutropenia in Arabs

  2009cited by this paper
• Recurrent pancreatitis without eosinophilia on clozapine rechallenge.

  2009cited by this paper
• Add-on filgrastim during clozapine rechallenge in patients with a history of clozapine-related granulocytopenia/agranulocytosis.

  2009cited by this paper
• Successful re-exposure to clozapine following uneventful rechallenge with olanzapine in a patient with neutropenia related to both agents.

  2008cited by this paper
• Ethnic Neutropenia and Clozapine

  2008cited by this paper
• Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia.

  2008cited by this paper
• Successful re-challenge with clozapine following development of clozapine-induced cardiomyopathy.

  2008cited by this paper
• Clozapine and granulocyte colony-stimulating factor: potential for long-term combination treatment for clozapine-induced neutropenia.

  2007cited by this paper
• A case of clozapine-induced paralytic ileus

  2007cited by this paper
• Lithium and clozapine rechallenge: a retrospective case analysis.

  2006cited by this paper
• Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

  2006cited by this paper
• Clozapine-Induced Systemic Lupus Erythematosus

  2006cited by this paper
• Rechallenge with clozapine following leucopenia or neutropenia during previous therapy

  2006cited by this paper
• Hematological adverse events in clozapine-treated children and adolescents.

  2005cited by this paper
• Rechallenge of late-onset neutropenia with clozapine.

  2005cited by this paper
• Continuing clozapine treatment despite neutropenia

  2004cited by this paper
• Clozapine-Related Myocarditis and Cardiomyopathy in an Australian Metropolitan Psychiatric Service

  2004cited by this paper
• Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMÜP program

  2004cited by this paper
• Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK.

  2003cited by this paper
• Management of treatment resistance in schizophrenia.

  2001cited by this paper
• Comprehensive care of schizophrenia: A textbook of clinical management

  2001cited by this paper
• Neuroleptic malignant syndrome associated with long-term clozapine treatment: report of a case and results of a clozapine rechallenge.

  2001cited by this paper
• Clozapine rechallenge after myocarditis.

  2001cited by this paper
• A second trial of clozapine in a case of granulocytopenia

  2000cited by this paper
• An unexpected and serious complication of treatment with the atypical antipsychotic drug clozapine.

  2000cited by this paper
• Developing clinical guidelines.

  1999cited by this paper
• Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF)

  1998cited by this paper
• Clozapine efficacy in tardive dyskinesia in schizophrenic patients

  1998cited by this paper
• Neuroleptic Malignant Syndrome and Clozapine Monotherapy

  1996cited by this paper
• Neuroleptic malignant syndrome associated with clozapine treatment.

  1995cited by this paper
• Recurrent pancreatitis on clozapine re-challenge

  1995cited by this paper
• Sertraline treatment of attention deficit hyperactivity disorder and Tourette's syndrome.

  1994cited by this paper
• Unsuccessful reexposure to clozapine.

  1994cited by this paper
• Unrelated agranulocytosis in a patient taking clozapine.

  1993cited by this paper
• Eosinophilia, clozapine, and pancreatitis.

  1992cited by this paper
• An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapine therapy: report of a case and results of a clozapine rechallenge.

  1992cited by this paper
• Rechallenge in clozapine-induced agranulocytosis.

  1992cited by this paper
• Neuroleptic malignant syndrome associated with clozapine use.

  1991cited by this paper
• Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

  1988cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• Tolerability and therapeutic effect of clozapine

  1985cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper

• A Review of Clinical Advances and Challenges in Clozapine-Induced Myocarditis

  2025cites this paper
• Clinical Outcomes and Factors Associated with Neuroleptic Malignant Syndrome in Older Patients: A Case Control Study

  2025cites this paper
• Managing treatment-resistant schizophrenia following clozapine cessation: a case report of xanomeline–trospium and olanzapine combination therapy

  2025cites this paper
• Late-Onset Neutropenia in Clozapine Users: Unrelated or Drug-Induced? A Case-Registry Analysis of Incidence, Characteristics, and Rechallenge Attempts.

  2025cites this paper
• Clozapine Re-challenge in a Patient With Pericarditis: A Case Report

  2025cites this paper
• Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis.

  2025cites this paper
• Clozapine-geïnduceerde cardiomyopathie: een multidisciplinaire afweging

  2025cites this paper
• Abnormal blood concentration changes in a 71-year-old female who survived a 10,000mg overdose of clozapine: a case report

  2024cites this paper
• Myocarditis on Clozapine 50 mg/d in a Patient With Parkinson's Disease

  2024cites this paper
• When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis

  2024influential citation
• Understanding clozapine-related blood dyscrasias. Developments, genetics, ethnicity and disparity: it's a CIN

  2024cites this paper
• Successful Clozapine Rechallenge After Clozapine-Induced Severe Anemia: A Case Report.

  2024cites this paper
• The Role of Case Series and Case Reports in Evidence-Based Medicine

  2024cites this paper
• Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review

  2024cites this paper
• Myocarditis in patients on long-term antipsychotics –mechanism, management and recent updates

  2023cites this paper
• Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?

  2023cites this paper
• Sicherheitsaspekte bei der Behandlung mit Clozapin

  2023cites this paper
• The ever-growing case for clozapine in the treatment of schizophrenia: an obligation for psychiatrists and psychiatry

  2023cites this paper
• Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia

  2023cites this paper
• Clozapine is the approved option in treatment-resistant schizophrenia and requires careful management

  2023cites this paper
• Successful clozapine rechallenge after myopericarditis: a case report

  2022influential citation
• Prevalence and clinical characteristics of COVID-19 in inpatients with schizophrenia in Wuhan, China

  2022cites this paper
• Transient Clozapine-induced Myocarditis Without Discontinuation of Medication: A Series of 2 Patients.

  2022cites this paper
• A Slow, Cautious, and Successful Clozapine Rechallenge After Myocarditis.

  2022cites this paper
• Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome

  2022cites this paper
• Catatonia and Schizophrenia in a Young Man with Autism Spectrum Disorder and Clozapine-Induced Myocarditis.

  2022cites this paper
• Successful rechallenge after clozapine-associated myocarditis

  2022cites this paper
• Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series

  2022cites this paper
• Monitoring Patients With Psychotic Disorders for Clozapine-Induced Myocarditis or Cardiomyopathy

  2022cites this paper
• Clozapine's multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia.

  2022cites this paper
• A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia

  2022cites this paper
• Successful rechallenge with clozapine after discontinuation due to drug‐induced pneumonia: A case report

  2022cites this paper
• Drug–drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs

  2022cites this paper
• Monitoring for myocarditis during treatment initiation with clozapine

  2021cites this paper
• Continuation of Treatment With Clozapine After an Episode of Neutropenia

  2021cites this paper
• Clozapine Is Better Tolerated in Younger Patients: Risk Factors for Discontinuation from a Nationwide Database in Japan

  2021cites this paper
• Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: a systematic case review

  2021cites this paper
• Demographic and clinical characteristics of patients who recommence clozapine following therapy interruptions

  2021cites this paper
• Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy

  2021cites this paper
• Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series

  2021cites this paper
• Clozapine re-challenge and initiation following neutropenia: a review and case series of 14 patients in a high-secure forensic hospital

  2021cites this paper
• Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review

  2021cites this paper
• A rare cause of agranulocytosis

  2021cites this paper
• Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.

  2021cites this paper
• Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real‐World Study Across Antipsychotics

  2020cites this paper
• A validated method for the simultaneous determination of quetiapine, clozapine and mirtazapine in post mortem blood and tissue samples.

  2020cites this paper
• In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine

  2020cites this paper
• How and when to use clozapine

  2020cites this paper
• Agranulocitosis secundaria a clozapina: a propósito de 2 casos

  2020cites this paper
• Real-world effectiveness of olanzapine and risperidone in the treatment of schizophrenia in Brazil over a 16-year follow-up period; findings and implications

  2020cites this paper
• Delayed-Onset Severe Neutropenia Associated With Clozapine With Successful Rechallenge at Lower Dose.

  2020cites this paper
• Successful Clozapine Re-Challenge After Suspected Clozapine-Induced Myocarditis

  2020cites this paper
• Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals

  2020cites this paper
• Nøytropeni ved behandling med antipsykotika

  2020cites this paper
• Clozapine rechallenge and initiation despite neutropenia- a practical, step-by-step guide

  2020cites this paper
• Successful clozapine rechallenge following recurrent clozapine-associated pancreatitis: a case report

  2020cites this paper
• The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder.

  2019cites this paper
• A comparative study of detection of myocarditis induced by clozapine: With and without cardiac monitoring.

  2019cites this paper
• Clozapine-Related Myocarditis and Rechallenge: A Case Series and Clinical Review.

  2019cites this paper
• Pericardial Effusion: Rare Adverse Effect of Clozapine

  2019cites this paper
• Protocol for Clozapine Rechallenge in a Case of Clozapine-Induced Myocarditis

  2019cites this paper
• Clozapine Re-Challenge and Initiation Despite Neutropenia and Outcomes from 14 Patients

  2019cites this paper
• Antidepressants

  2019cites this paper
• Failure of rechallenge clozapine after agranulocytosis: A case report.

  2019cites this paper
• CLOZAPINE RECHALLENGE WITH LITHIUM AFTER DOUBLE INDUCED NEUTROPENIA: A CASE REPORT

  2018cites this paper